Sarepta price target lowered to $182 from $200 at Piper Sandler
Piper Sandler analyst Biren Amin lowered the firm’s price target on Sarepta (SRPT) to $182 from $200 and keeps an Overweight rating on the ...
Sarepta Therapeutics Receives Buy Rating from Gil Blum: Strategic Partnerships and Financial Stability Highlight Growth Potential
Gil Blum, an analyst from Needham, reiterated the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target was ...